RANI Stock Overview
Operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Rani Therapeutics Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.60 |
52 Week High | US$8.75 |
52 Week Low | US$1.82 |
Beta | 0.13 |
11 Month Change | 14.04% |
3 Month Change | -22.85% |
1 Year Change | 29.35% |
33 Year Change | -87.18% |
5 Year Change | n/a |
Change since IPO | -76.36% |
Recent News & Updates
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Jul 16Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Mar 20Recent updates
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Jul 16Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Mar 20Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Aug 08We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Feb 13Shareholder Returns
RANI | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 10.6% | 1.4% | 1.1% |
1Y | 29.4% | 19.4% | 32.2% |
Return vs Industry: RANI exceeded the US Pharmaceuticals industry which returned 19.4% over the past year.
Return vs Market: RANI underperformed the US Market which returned 32.2% over the past year.
Price Volatility
RANI volatility | |
---|---|
RANI Average Weekly Movement | 22.8% |
Pharmaceuticals Industry Average Movement | 9.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RANI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RANI's weekly volatility has increased from 16% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 140 | Talat Imran | www.ranitherapeutics.com |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
Rani Therapeutics Holdings, Inc. Fundamentals Summary
RANI fundamental statistics | |
---|---|
Market cap | US$113.22m |
Earnings (TTM) | -US$30.58m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs RANI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RANI income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$30.58m |
Earnings | -US$30.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.04 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 531.5% |
How did RANI perform over the long term?
See historical performance and comparison